Somatostatin analogues in the control of neuroendocrine tumours: efficacy and mechanisms.

Somatostatin analogues in the control of neuroendocrine tumours: efficacy and mechanisms.

Neuroendocrine tumours (NETs) represent a heterogeneous family of neoplasms, which may develop from different endocrine glands (such as the pituitary, the parathyroid or the neuroendocrine adrenal glands), endocrine islets (within the thyroid or pancreas) as well as from endocrine cells dispersed be...

書誌詳細
主要な著者:	Grozinsky-Glasberg, S, Shimon, I, Korbonits, M, Grossman, AB
フォーマット:	Journal article
言語:	English
出版事項:	2008

類似資料

The role of somatostatin analogues in the treatment of neuroendocrine tumours.
著者:: Grozinsky-Glasberg, S, 等
出版事項: (2008)

Treatment of advanced neuroendocrine tumours with radiolabelled somatostatin analogues.
著者:: Kaltsas, G, 等
出版事項: (2005)

Imaging neuroendocrine tumours with radiolabelled somatostatin analogues and X-ray computed tomography: a comparative study.
著者:: King, C, 等
出版事項: (1993)

Are serotonin metabolite levels related to bone mineral density in patients with neuroendocrine tumours?
著者:: Gupta, P, 等
出版事項: (2014)

Localization of neuroendocrine tumours and insulinomas using radiolabelled somatostatin analogues, 123I-Tyr3-octreotide and 111In-pentatreotide.
著者:: Ur, E, 等
出版事項: (1993)

The somatostatin analogue octreotide inhibits growth of small intestine neuroendocrine tumour cells.
著者:: Su-Chen Li, 等
出版事項: (2012-01-01)

Somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine tumours, current aspects and new perspectives
著者:: Baldelli Roberto, 等
出版事項: (2010-03-01)

Somatostatin analogues therapy in gastroenteropancreatic neuroendocrine tumours: current aspects and new perspectives
著者:: Roberto eBaldelli
出版事項: (2014-02-01)

Are serotonin metabolite levels related to bone mineral density in patients with neuroendocrine tumours?
著者:: Sen Gupta, P, 等
出版事項: (2014)

Transcriptome of GH-producing pituitary neuroendocrine tumours and models are significantly affected by somatostatin analogues
著者:: Rihards Saksis, 等
出版事項: (2023-02-01)

Efficacy of somatostatine analogues in survival and quality of life of a frail patient with poorly differentiated biliary neuroendocrine tumour
著者:: Marco Alì, 等
出版事項: (2015-10-01)

Somatostatin analogues stimulate p27 expression and inhibit the MAP kinase pathway in pituitary tumours.
著者:: Hubina, E, 等
出版事項: (2006)

Comparison of somatostatin receptor expression in patients with neuroendocrine tumours with and without somatostatin analogue treatment imaged with [18F]SiTATE
著者:: Ralf S. Eschbach, 等
出版事項: (2023-01-01)

Somatostatin Analogue Treatment Increases AIP Protein Expression in Somatotroph Tumours from Patients with Acromegaly and in GH3 Cells in vitro.
著者:: Chahal, H, 等
出版事項: (2011)

Somatostatin receptor biology in neuroendocrine and pituitary tumours: part 1--molecular pathways.
著者:: Cakir, M, 等
出版事項: (2010)

Somatostatin receptor biology in neuroendocrine and pituitary tumours: part 2--clinical implications.
著者:: Cakir, M, 等
出版事項: (2010)

Distinct mechanisms of hypoglycaemia in patients with somatostatin‐secreting neuroendocrine tumours
著者:: Peter Wiesli, 等
出版事項: (2019-10-01)

Evaluation of the Association between Serotonin and Bone Mineral Density in Patients with Neuroendocrine Tumors
著者:: Den Gupta, P, 等
出版事項: (2011)

The Global mTOR Inhibitor Torin1 Is More Effective than the mTORC1 Inhibitor, Everolimus, Alone or in Combination with Histone Deacetylase Inhibitors, in Suppressing Neuroendocrine Tumor Cell Proliferation
著者:: Grozinsky-Glasberg, S, 等
出版事項: (2011)

AIP Mediates the Effects of Somatostatin Analogues in Acromegaly - Evidence from Clinical and Experimental Studies.
著者:: Chahal, H, 等
出版事項: (2010)

Update on neuroendocrine tumours
著者:: Grossman, AB
出版事項: (2012)

Interaction between somatostatin analogues and targeted therapies in neuroendocrine tumor cells.
著者:: Sebastian Krug, 等
出版事項: (2019-01-01)

Patient reported symptoms, coping and quality of life during somatostatin analogue treatment for metastatic small- intestinal neuroendocrine tumours
著者:: Halfdan Sorbye, 等
出版事項: (2020-06-01)

Current treatment strategies for patients with advanced gastroenteropancreatic neuroendocrine tumors (GEP-NETs)
著者:: Inbal Uri, 等
出版事項: (2018-07-01)

Current concepts in the diagnosis and management of type 1 gastric neuroendocrine neoplasms.
著者:: Kaltsas, G, 等
出版事項: (2014)

Comparison of somatostatin analog and meta-iodobenzylguanidine radionuclides in the diagnosis and localization of advanced neuroendocrine tumors.
著者:: Kaltsas, G, 等
出版事項: (2001)

Chronic Treatment with Somatostatin Analogues in Recurrent Type 1 Gastric Neuroendocrine Tumors
著者:: Fernando Sebastian-Valles, 等
出版事項: (2023-03-01)

Initiation of Somatostatin analogues for neuroendocrine tumor patients: a cost-effectiveness analysis
著者:: Sheila D. Rustgi, 等
出版事項: (2021-05-01)

Treatment with somatostatin analogues and PRRT in metastatic middle ear adenoma with neuroendocrine features
著者:: Joana Lima Ferreira, 等
出版事項: (2021-05-01)

Patient And Nurse Experience Of Using Somatostatin Analogues To Treat Gastroenteropancreatic Neuroendocrine Tumors: Results Of The Somatostatin Treatment Experience Trial (STREET)
著者:: Ström T, 等
出版事項: (2019-10-01)

Expression of Somatostatin Receptor 2 in Somatotropinoma Correlated with the Short-Term Efficacy of Somatostatin Analogues
著者:: Wenjuan Liu, 等
出版事項: (2017-01-01)

Pituitary imaging using a labelled somatostatin analogue in acromegaly.
著者:: Ur, E, 等
出版事項: (1992)

Radionuclide treatment of neuroendocrine tumours with the novel radiolabelled analogue Y-90-SMT 487
著者:: Carroll, P, 等
出版事項: (2003)

Growth hormone-releasing peptides (GHRP) and their analogues
著者:: Korbonits, M, 等
出版事項: (1996)

[Growth hormone-releasing peptides (GHRP) and their analogues]
著者:: Korbonits, M, 等
出版事項: (1996)

Octreotide and the mTOR inhibitor RAD001 (everolimus) block proliferation and interact with the Akt-mTOR-p70S6K pathway in a neuro-endocrine tumour cell Line.
著者:: Grozinsky-Glasberg, S, 等
出版事項: (2008)

Paraneoplastic syndromes secondary to neuroendocrine tumours.
著者:: Kaltsas, G, 等
出版事項: (2010)

Antiangiogenic effects of somatostatin analogues.
著者:: García de la Torre, N, 等
出版事項: (2002)

Chemokines modulate the tumour microenvironment in pituitary neuroendocrine tumours
著者:: Pedro Marques, 等
出版事項: (2019-11-01)

Optimal dosage interval for depot somatostatin analogue therapy in acromegaly requires individual titration.
著者:: Jenkins, P, 等
出版事項: (2000)